Detailed Narrative
Robust Financial Performance in FY25
Marksans Pharma achieved an all-time high in both revenue and profit for FY25. Operating revenue increased by 20.5% year-on-year to ₹2,623 crores, up from ₹2,177 crores in the previous year. Profit after tax (PAT) also saw a significant growth of 21.5% year-on-year, reaching ₹383 crores compared to ₹315 crores in FY24. The gross margin expanded by 407 basis points to 56.4% for the full year, indicating improved operational efficiency and product mix.
Q4 FY25 Performance and Margin Dynamics
In Q4 FY25, the company reported operating revenue of ₹708.5 crores, a 26.5% increase year-on-year, and PAT of ₹90.7 crores, up 16.9% year-on-year. However, the EBITDA margin for the quarter stood at 17.8%, a decrease of 183 basis points from the same quarter last year. This decline was primarily attributed to an increase in employee expenses due to headcount additions at the acquired Goa facility and higher R&D expenses. A slower cough and cold season also impacted the product mix during the quarter.
Teva Facility Ramp-up and Capacity Expansion
The acquired Teva facility is progressing well, with management indicating that current utilization is trending at ₹400-500 crores, aiming to reach ₹600-700 crores in the latter part of the year and eventually ₹1,000 crores. The facility is currently producing around 350 million tablets, with an objective to cross 450-500 million in the first half and then 600-700 million. Management expects to meet 50-60% of its historical capacity growth targets within the next six months, with capacity expansion initiatives advancing to materialize operating leverage benefits in the next financial year.
Strategic Focus on Product Pipeline and Market Growth
Marksans Pharma continues to focus on expanding its product pipeline, having commercialized 58 SKUs during the year and with 79 more products in the pipeline. In the UK, 12 products received approval, and 18 additional products were filed. The company aims to launch approximately 70 new products across various therapeutic segments by September. The US market remains a significant growth driver, with the current order book at $220 million and a target to reach $300 million within two years, driven by new product launches and market share gains.
Capital Allocation and Shareholder Returns
The company maintains a debt-free status, with a cash balance of ₹704 crores as of March 31, 2025. The Board recommended a dividend of ₹0.8 per equity share, representing 80% of the face value. Capital expenditure for FY25 was ₹173 crores, and for FY26, it is projected to be $8-10 million. Marksans is actively pursuing European M&A opportunities, with potential deals in the €30-40 million range, and plans to allocate a minimum of ₹400 crores for these strategic initiatives and plant CAPEX.
US Tariffs and Working Capital Management
Management addressed concerns regarding potential US tariffs, stating that if tariffs are significant (e.g., 10% or more), they would likely be passed on to consumers, as retailers cannot absorb such costs. No pre-buying activity was observed in Q1 FY26 due to tariff anticipation. The working capital cycle increased to 127 days, primarily due to inventory build-up for new product launches, but is expected to remain stable within the 125-135 day range. Freight costs, which were high in the first two quarters of FY25, have stabilized and are expected to return to 4% of sales in FY26.